Drug researchers pursue new lines of attack against COVID-19 5/15/20 | RVX:CA Message Board Posts


Resverlogix Corp.

  RVX:CA website

RVX:CA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27120 of 27130  at  5/24/2020 10:37:57 AM  by

rndtbl


Drug researchers pursue new lines of attack against COVID-19 5/15/20

 
Bromodomain inhibitors could also be deployed to interrupt another interaction identified in the Nature paper, between SARS-CoV-2 transmembrane envelope protein (E) and BRD2 and/or BRD4. “This potential mechanism of action could be relevant in the context of the secondary immune-related consequences of SARS-CoV-2 infection,” says Andy Conery, director of Functional Genomics at Constellation Pharmaceuticals. Those bromodomain inhibitors already in the clinic include Resverlogix’s apabetalone, in phase 3 trials for cancer and phase 1 for pulmonary arterial hypertension; AbbVie’s ABBV-744, in phase 1 for cancer; and Constellation Pharmaceuticals’ CPI-0610, in phase 2 for cancer. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1  
   Views: 277 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...